Logo image
Back
Patients at high risk of death after lung-volume-reduction surgery
Journal article   Open access   Peer reviewed

Patients at high risk of death after lung-volume-reduction surgery

Alfred Fishman, Henry Fessler, Fernando Martinez, Robert J McKenna Jr, Keith Naunheim, Steven Piantadosi, Gail Weinmann, Robert Wise and National Emphysema Treatment Trial Research Group
The New England journal of medicine, Vol.345(15), pp.1075-1083
10/11/2001
DOI: 10.1056/NEJMoa11798
PMID: 11596586
url
https://doi.org/10.1056/NEJMoa11798View
Published (Version of record) Open Access

Abstract

Lung-volume-reduction surgery is a proposed treatment for emphysema, but optimal selection criteria have not been defined. The National Emphysema Treatment Trial is a randomized, multicenter clinical trial comparing lung-volume-reduction surgery with medical treatment. After evaluation and pulmonary rehabilitation, we randomly assigned patients to undergo lung-volume-reduction surgery or receive medical treatment. Outcomes were monitored by an independent data and safety monitoring board. A total of 1033 patients had been randomized by June 2001. For 69 patients who had a forced expiratory volume in one second (FEV1) that was no more than 20 percent of their predicted value and either a homogeneous distribution of emphysema on computed tomography or a carbon monoxide diffusing capacity that was no more than 20 percent of their predicted value, the 30-day mortality rate after surgery was 16 percent (95 percent confidence interval, 8.2 to 26.7 percent), as compared with a rate of 0 percent among 70 medically treated patients (P<0.001). Among these high-risk patients, the overall mortality rate was higher in surgical patients than medical patients (0.43 deaths per person-year vs. 0.11 deaths per person-year; relative risk, 3.9; 95 percent confidence interval, 1.9 to 9.0). As compared with medically treated patients, survivors of surgery had small improvements at six months in the maximal workload (P= 0.06), the distance walked in six minutes (P=0.03), and FEV1 (P<0.001), but a similar health-related quality of life. The results of the analysis of functional outcomes for all patients, which accounted for deaths and missing data, did not favor either treatment. Caution is warranted in the use of lung-volume-reduction surgery in patients with emphysema who have a low FEV1 and either homogeneous emphysema or a very low carbon monoxide diffusing capacity. These patients are at high risk for death after surgery and also are unlikely to benefit from the surgery.
 Probability Pulmonary Emphysema - physiopathology Pneumonectomy - mortality Humans Middle Aged Risk Factors Male Pulmonary Emphysema - surgery Survival Rate Treatment Outcome Pulmonary Emphysema - therapy Contraindications Patient Selection Forced Expiratory Volume Pulmonary Diffusing Capacity Female Aged Pulmonary Emphysema - mortality

Details

Metrics

18 Record Views
452 Times Cited - Web of Science
Logo image